

This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

ONE-POT SYNTHESIS OF NOVEL 10-ARYL[1,2,4]TRIAZOLO[3',4':2,3][1,3,4]-THIADIAZEPINO[6,7-c]QUINOLIN-6(5H)-ONES

A. Jayashree^a; Malleshwar Darbarwar^a

^a Department of Chemistry, Osmania University, Hyderabad, AP, INDIA

To cite this Article Jayashree, A. and Darbarwar, Malleshwar(1993) 'ONE-POT SYNTHESIS OF NOVEL 10-ARYL[1,2,4]TRIAZOLO[3',4':2,3][1,3,4]-THIADIAZEPINO[6,7-c]QUINOLIN-6(5H)-ONES', Organic Preparations and Procedures International, 25: 6, 659 – 663

To link to this Article: DOI: 10.1080/00304949309356261

URL: <http://dx.doi.org/10.1080/00304949309356261>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**ONE-POT SYNTHESIS OF NOVEL 10-ARYL[1,2,4]TRIAZOLO[3',4':2,3][1,3,4]-
THIADIAZEPINO[6,7-c]QUINOLIN-6(5H)-ONES**

A. Jayashree and Malleshwar Darbarwar*

*Department of Chemistry, Osmania University
Hyderabad 500 007, A.P., INDIA*

The newly reported 3,4-heteroannelated quinolin-2-ones are associated with a variety of pharmacological properties.¹ Due to high incidence of desirable pharmacological and physiological properties of these heterocycles, new synthetic methods to afford these heterocycles are gaining importance. Thiadiazepines and triazoles also contribute a wide range of therapeutically interesting drug candidates. Recent attempts were made to incorporate the 1,2,4-triazole nucleus into a wide variety of pharmacologically active compounds such as antihistamines, antianxiety agents and sedatives.² Thus, certain *s*-triazolobenzodiazepines like alprazolam, triazolam and adinazolam have been reported to have very high anxiolytic and hypnotic activities in humans.³ In continuation of our interest in hitherto unknown 3,4-heteroannelated quinolin-2-ones⁴ and , as a result of the importance of triazolodiazepines in the pharmacological field, the synthesis of the title compounds is reported in the present communication. For the synthesis of 10-aryl[1,2,4]triazolo[3',4':2,3][1,3,4]thiadiazepino[6,7-*c*]quinolin-6(5H)-ones, 4-chloro-3-formylquinolin-2(1H)-ones (1)⁵ and 5-aryl-4-amino-3-mercapto(4H)-1,2,4-triazoles (2)⁶ were selected as the suitable starting materials.


As an illustrative example, the reaction of 1-methyl-4-chloro-3-formylquinolin-2-one (1a) with an equimolar quantity of 5-*o*-tolyl-4-amino-3-mercapto-(4H)-1,2,4-triazole (2b) in refluxing methanol furnished a single compound in 95% yield (mp. 280-282°). The mass spectrum of the compound displayed a molecular ion peak at *m/z* 373 (95%) and a *M*+2 peak at 375 (4%). The IR spectrum (KBr) revealed stretching frequencies due to N-C=O and C=N groups at 1630 and 1600 cm⁻¹. The ¹H NMR spectrum (CDCl₃) displayed signals at δ 2.35 (s, 3H, Ar-CH₃), 3.75 (s, 3H, N-CH₃), 7.2-8.2 (m, 7H, arom), 8.45 (d, 1H, arom, *J* = 8.3 Hz, C¹-H) and 8.65 (s, 1H, CH=N). With the aid of above spectral data and elemental analysis, the structure of the compound has been assigned as 5-methyl-10-(2-methylphenyl)[1,2,4]triazolo[3',4':2,3][1,3,4]thiadiazepino[6,7-*c*]quinolin-6(5H)-one (4b). The ¹³C NMR spectrum of this compound was recorded, and the assignments are presented in Table 3.

The reaction involves the nucleophilic addition of -NH₂ group of 5-aryl-4-amino-3-mercapto-(4H)-1,2,4-triazole (2) to the carbonyl group of 4-chloro-3-formylquinolin-2(1H)-ones, followed by

dehydration to afford the intermediate 3. Nucleophilic attack of sulfur on the electron deficient carbon in intermediate 3, and simultaneous ring closure leads to the formation of another intermediate from which the elimination of chloride ion results in the formation of title compounds 4. Adopting the above procedure, fourteen other substituted 10-aryl[1,2,4]triazolo[3',4':2,3][1,3,4]thiadiazepino[6,7-c]quinolin-6(5H)-ones (4b-o) were synthesized in 70-95% yields. The structures assigned to these compounds (4a-o) are well supported by the spectral properties and elemental analysis. The mass fragmentation pattern of the compounds (4a-o) is similar, and the important ions, along with M⁺ are presented in Table 1. ¹³C-NMR spectra of compounds 4d and 4j were recorded, and the assignments are given in Table 3.

The reaction of 1a and 2b has been carried out in DMF in the presence of K₂CO₃ at room temperature and also in THF at room temperature. In both these cases, the same product 4b was isolated, but in considerably lower yields (70, 75%). Therefore, the title compounds were synthesized by reacting 1 and 2 in refluxing methanol.

Scheme



EXPERIMENTAL SECTION

Melting points reported are uncorrected and were determined in capillaries using a sulfuric acid bath. UV spectra were taken in methanol IR spectra were obtained in KBr and ¹H NMR were recorded in CDCl₃.

Synthesis of 10-Aryl[1,2,4]triazolo[3',4':2,3][1,3,4]thiadiazepino[6,7-c]quinolin-6(5H)-ones (4a-o). General Procedure. - To a solution of 4-chloro-3-formylquinolin-2(1H)-one (1, 1 mmole) in absolute methanol (10 mL), an equimolar quantity of the appropriate 5-aryl-4-amino-3-mercapto-(4H)-1,2,4-triazole (2, 1 mmole) was added and refluxed for 10-75 minutes. The title compounds sepa-

10-ARYL[1,2,4]TRIAZOLO[3',4':2,3][1,3,4]-THIADIAZEPINO[6,7-*c*]QUINOLIN-6(5*H*)-ONES

rated out from the reaction mixture as yellow-orange colored crystalline solids while hot. The reaction mixture was cooled, filtered, residue washed with little methanol and dried. The crude 10-aryl[1,2,4]triazolo[3',4':2,3][1,3,4]thiadiazepino[6,7-*c*]quinolin-6(5*H*)-ones (**4a-o**), thus obtained were crystallized from methanol:benzene (1:1) solvent mixture.

TABLE 1. Physical Constants of Compounds 4

Compd	m.p. (°C)	Yield (%)	Elemental analysis (Found)			EIMS m/z (%)
			C	H	N	
4a	290-292	80	63.47 (63.61)	3.67 (3.70)	19.49 (19.62)	359 (M ⁺ 100), 358 (30), 330 (5) 242 (30), 117 (5)
4b	280-282	95	64.38 (64.51)	4.06 (4.12)	18.78 (18.90)	373 (M ⁺ 95), 372 (20), 242 (20), 131 (100)
4c	282-284	90	56.49 (56.62)	2.91 (2.78)	20.76 (20.90)	—
4d	240-241	95	61.62 (61.45)	3.86 (3.93)	17.90 (17.77)	—
4e	250-251	95	61.67 (61.81)	3.80 (3.82)	17.93 (17.78)	389 (M ⁺ 20), 388 (15), 357 (5), 242 (5), 147(5).
4f	248-250	80	64.37 (64.51)	4.03 (4.12)	18.79 (18.90)	373 (M ⁺ 100), 372 (20), 330 (5), 256 (30), 117 (10)
4g	250-252	95	65.06 (65.21)	4.41 (4.50)	18.08 (18.23)	387 (M ⁺ 80), 386 (15), 256 (20), 131 (100)
4h	307-309	70	57.42 (57.28)	3.31 (3.25)	20.06 (20.21)	—
4i	156-158	90	62.51 (62.37)	4.23 (4.31)	17.31 (17.25)	403 (M ⁺ 90), 402 (10), 256 (30), 147 (20)
4j	160-162	85	62.53 (62.61)	4.25 (4.32)	17.37 (17.51)	403 (M ⁺ 100), 402 (20), 256 (40), 147 (20)
4k	290-292	80	68.33 (68.51)	3.51 (3.48)	16.66 (16.70)	421 (M ⁺ 100), 330 (5), 304 (20), 117 (5)
4l	330-332	95	68.90 (68.83)	3.91 (3.85)	16.08 (16.09)	435 (M ⁺ 90), 304 (30), 131 (80)
4m	286-288	70	61.73 (61.91)	3.06 (3.10)	18.09 (18.20)	466 (M ⁺ 50), 304 (10), 162 (10)
4n	260-261	95	66.51 (66.36)	3.72 (3.63)	15.54 (15.71)	451 (M ⁺ 100), 304 (40), 147 (20)
4o	170-172	70	66.51 (66.45)	3.76 (3.81)	15.53 (15.71)	—

TABLE 2. Spectral Data of Compounds 4

Compd	IR cm ⁻¹	UV λ_{\max} (log ϵ)	¹ H NMR δ ppm, J (Hz)
4a	1640 1600	473.1 (2.82), 375.2 (4.11), 305.4 (4.23), 241.0 (4.77)	3.7 (s, 3H), 7.0-8.2 (m, 9H, arom), 8.4 (s, 1H)
4b	1630 1600	472.6 (2.84), 321.1 (4.39), 236.3 (4.90)	2.35 (s, 3H), 3.75 (s, 3H), 7.2-8.2 (m, 7H, arom), 8.45 (d, 1H, arom, J = 8.3), 8.65 (s, 1H).
4c	1640 1600	472.8 (2.73), 385.8 (4.20), 375.5 (4.22), 229.3 (4.77) 210.4 (4.72)	3.75 (s, 3H), 7.2-8.2 (m, 7H, arom), 8.45 (d, 1H, arom, J = 8.3), 8.6 (s, 1H)
4d	1645 1600	473.1 (2.72), 375.4 (4.26), 297.9 (4.43), 231.5 (4.93)	3.7 (s, 3H), 3.85 (s, 3H), 7.0-7.8 (m, 7H, arom), 8.4 (d, 1H, J = 8), 8.7 (s, 1H).
4e	1640 1600	473.6 (2.64), 375.5 (4.08), 244.3 (4.67), 203.5 (4.75)	3.7 (s, 3H), 3.85 (s, 3H), 6.9-8.0 (m, 7H, arom), 8.3 (d, 1H, arom, J = 8), 8.6 (s, 1H).
4f	1620 1600	472.5 (2.62), 375.3 (4.21), 300.0 (4.53), 238.8 (4.51), 209.2 (4.80)	1.4 (t, 3H, J = 6.6), 4.25 (q, 2H, J = 6.6), 7.2-8.05 (m, 8H, arom), 8.3 (d, 1H, J = 8, arom), 8.6 (s, 1H).
4g	1640 1600	473.0 (2.64), 370.9 (4.45), 306.1 (4.53), 236.2 (4.62), 207.8 (4.79)	1.25 (t, 3H, J = 6.8), 2.25 (s, 3H), 4.25 (q, 2H, J = 6.8), 7.25-8.1 (m, 7H, arom), 8.5 (d, 1H, arom, J = 8.3), 8.6 (s, 1H).
4h	1640 1600	472.0 (2.95), 379.0 (4.21), 339.4 (4.22), 335.2 (4.23), 285.8 (4.32), 239.4 (4.85), 210.6 (4.74)	1.45 (t, 3H, J = 6.8), 4.4 (q, 2H, J = 6.8), 7.3-8.2 (m, 7H, arom), 8.4 (d, 1H, arom, J = 8.0), 8.85 (s, 1H).
4i	1640 1600	473.0 (2.62), 376.5 (4.42), 298.4 (4.58), 231.8 (4.82)	1.4 (t, 3H, J = 7.1), 3.9 (s, 3H), 4.4 (q, 2H, J = 7.1), 7.05-7.8 (m, 7H, arom), 8.45 (d, 1H, arom, J = 8.2), 8.8 (s, 1H)
4j	1630 1600	472.5 (2.73), 369.6 (4.31), 320.3 (4.34), 248.6 (4.90)	1.4 (t, 3H, J = 7.00), 3.88 (s, 3H), 4.38 (q, 2H, J = 7.00), 6.87-7.8 (m, 7H, arom), 8.4 (d, 1H, arom, J = 8.3), 8.8 (s, 1H)
4k	1645 1600	473.4 (2.62), 342.2 (4.22), 268.0 (4.44), 210.0 (4.77)	6.75-8.2 (m, 13H, arom), 8.4 (d, 1H, arom, J = 8), 8.8 (s, 1H).
4l	1645 1600	472.2 (2.66), 345.0 (4.31), 273.9 (4.31), 210.4 (4.88)	2.25 (s, 3H), 6.7-8.3 (m, 12H, arom), 8.5 (d, 1H, arom, J = 8.2), 8.8 (s, 1H)
4m	1645 1610	472.8 (2.99), 345.4 (4.15), 273.3 (4.35), 234.4 (4.65), 209.3 (4.60)	6.8-8.3 (m, 12H, arom), 8.5 (d, 1H, arom, J = 8.0), 8.85 (s, 1H).
4n	1650 1600	473.1 (2.73), 345.9 (4.44), 275.5 (4.14), 235.9 (4.69), 210.0 (4.90)	3.95 (s, 3H), 6.75-8.2 (m, 12H, arom), 8.5 (d, 1H, arom, J = 8.3), 8.8 (s, 1H)
4o	1645 1610	473.4 (2.73), 340.2 (4.23), 275.6 (4.40), 234.6 (4.88), 201.2 (4.40)	3.85 (s, 3H), 6.7-8.2 (m, 12H, arom), 8.45 (d, 1H, arom, J = 8.2), 8.8 (s, 1H).

TABLE 3. ¹³C NMR Data of Compounds 4

Compd	Solvent	δ ppm (assignments) J (Hz)
4b	TFA	21.17 (C-7'), 33.24 (C-8'), 119.58 (C-4), 122.54 (C-13b), 125.62 (C-1), 128.71 (C-2), 129.54 (C-6a), 130.65 (C-2'), 133.29 (C-6'), 134.51 (C-3, C-4'), 137.49 (C-5'), 139.54 (C-3'), 142.08 (C-1'), 143.55 (C-4a), 150.47 (C-13a), 152.64 (C-10), 157.34 (C-12a), 162.84 (C-6) and 165.68 (C-7).
4d	TFA	31.06 (q, J = 83.6, C-8'), 55.96 (q, J = 83.6, C-7'), 115.99 (d, J = 117.1, C-4'), 116.66 (d, J = 139.4, C-2'), 120.20 (s, C-13b), 121.36 (d, J = 117.1, C-6'), 122.87 (d, J = 125.5, C-4), 123.49 (s, C-1'), 126.56 (d, J = 139.4, C-1), 128.38 (d, J = 133.8, C-2), 128.79 (s, C-6a), 132.02 (d, J = 125.5, C-3), 137.36 (d, J = 125.5, C-5'), 141.20 (s, C-4a), 148.50 (s, C-13a), 150.16 (s, C-10), 153.04 (s, C-12a), 160.50 (s, C-3'), 163.30 (d, J = 139.4, C-7)
4j	DMSO- <i>d</i> ₆	12.57 (C-9'), 37.41 (C-8'), 55.32 (C-7'), 114.19 (C-3', C-5'), 115.41 (C-4), 118.56 (C-13b), 121.19 (C-1), 127.66 (C-2), 128.0 (C-3, C-6'), 129.59 (C-2'), 134.25 (C-6a), 139.12 (C-1'), 144.26 (C-4a), 149.52 (C-13a), 150.12 (C-10), 152.20 (C-12a), 157.72 (C-4'), 160.21 (C-6), 160.94 (C-7).

Acknowledgement.- One of the authors (A. J.) gratefully acknowledges the UGC New Delhi, for awarding a Senior research Fellowship during this work.

REFERENCES

1. J. E. Ombetta, S. Lyet, A. Xicluna, J. F. Robert and J. J. Panouse, *Ann. Pharm. Fr.*, **46**, 377 (1989).
2. a) P. J. Kothari, S. P. Singh, S. S. Parmar and V. I. Stenberg, *J. Heterocycl. Chem.*, **17**, 1393 (1980); b) A. Rudzik and J. Hester, Abstracts of Great Lakes regional ACS Meeting, Medicinal Chemistry Section, Paper **52**, 32 (1973).
3. a) T. M. Itil, N. Polvan, S. Egilmez, B. Saletu and J. Marasa, *Curt. Ther. res. Clin. Exp.*, **15**, 603 (1973); b) R. I. H. Wang and S. L. Stockdalee, *J. Int. Med. Res.*, **1**, 600 (1973).
4. a) A. Jayashree, V. Sudhakar Rao and M. Darbarwar, *Synth. Commun.*, **20**, 919 (1990); b) V. Sudhakar Rao and M. Darbarwar, *Synthesis*, 139 (1989).
5. K. A. Khan and A. Shoeb, *Indian J. Chem.*, **24B**, 62 (1985).
6. a) E. Hoggarth, *J. Chem. Soc.*, 4811 (1952); b) J. R. Reid and N. D. Heindel, *J. Heterocycl. Chem.*, **13**, 925 (1976).

(Received December 7, 1992; in revised form June 24, 1993)